Hikma Pharmaceuticals PLC (HIK.LN), a speciality pharmaceutical company, said Monday that it has signed an exclusive agreement to represent BioCryst in respect of its anti-viral product peramivir for pandemic flu treatment stockpiling opportunities with governments in the Middle East and North Africa region.

-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.